Surrozen (SRZN) Other Operating Expenses (2020 - 2023)
Surrozen (SRZN) posted quarterly Other Operating Expenses of $40000.0 for Q4 2023, down 97.34% quarter-over-quarter from $1.5 million in Q3 2023.
Analysis
Surrozen (SRZN) Other Operating Expenses (2020 - 2023) Analysis & Trends
Surrozen's Other Operating Expenses history runs 3 years deep, the most recent figure standing at $40000.0 for Q4 2023.
- In Q4 2023, Other Operating Expenses changed N/A year-over-year to $40000.0; the TTM figure through Sep 2024 stood at $40000.0 (down 98.53% YoY), while the FY2023 annual figure was $2.8 million, changed N/A from the prior year.
- Other Operating Expenses for Q4 2023 stood at $40000.0, down from $1.5 million in the prior quarter.
- The five-year high for Other Operating Expenses was $1.5 million in Q3 2023, with the low at -$39.6 million in Q3 2021.
- The 3-year median for Other Operating Expenses is $40000.0 (2023), against an average of -$9.4 million.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Surrozen | 258.80 Mn | 258.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 40,000.00 |
| Sep 30, 2023 | 1.51 Mn |
| Mar 31, 2023 | 1.21 Mn |
| Sep 30, 2021 | -39.58 Mn |
| Dec 31, 2020 | -10.40 Mn |